- DocumentGW Law China IP Conference 2013încărcat deFDA Lawyers Blog
- DocumentGilead Citizen Petitionîncărcat deFDA Lawyers Blog
- DocumentClinical Data Guidanceîncărcat deFDA Lawyers Blog
- DocumentClinical Data Guidanceîncărcat deFDA Lawyers Blog
- DocumentAcetadote CP denial.pdfîncărcat deFDA Lawyers Blog
- DocumentFDLI US-Brazil Program 2012încărcat deFDA Lawyers Blog
- DocumentJazz's Xyrem Citizen Petitionîncărcat deFDA Lawyers Blog
- DocumentACI Clinical Trials 2012încărcat deFDA Lawyers Blog
- DocumentQ1 Productions Regulatory Clearance & Commercialization of Generic Drugs & Biosimilarsîncărcat deFDA Lawyers Blog
- DocumentViroPharma Citizen Petition Denialîncărcat deFDA Lawyers Blog
- DocumentTeam Copaxoneîncărcat deFDA Lawyers Blog
- DocumentPIV Disputes 2012încărcat deFDA Lawyers Blog
- DocumentSafety Data Collection Guidanceîncărcat deFDA Lawyers Blog
- DocumentCitizen Petition Regulation Amendmentsîncărcat deFDA Lawyers Blog
- DocumentFY2011încărcat deFDA Lawyers Blog
- DocumentDe Novo Guidanceîncărcat deFDA Lawyers Blog
- DocumentHomeopathicCPîncărcat deFDA Lawyers Blog
- DocumentACI Maximizing Pharmaceutical Patent Life Cycles 2011 NYCîncărcat deFDA Lawyers Blog
- DocumentWasson Associates Cornerîncărcat deFDA Lawyers Blog
- DocumentFinal Rule on Exemption for Substantial Equivalenceîncărcat deFDA Lawyers Blog
- DocumentFDA Pathway to Global Product Safety and Qualityîncărcat deFDA Lawyers Blog
- DocumentFLH BIO 2011 Brochureîncărcat deFDA Lawyers Blog
- DocumentAlliance Petition Dietary Supplementsîncărcat deFDA Lawyers Blog
- DocumentSubmission of Summary Bio Equivalence Data for ANDAs Guidanceîncărcat deFDA Lawyers Blog
- DocumentViroPharma Complaint Dismissedîncărcat deFDA Lawyers Blog
- Documentguidanceîncărcat deFDA Lawyers Blog
- DocumentUse Code Chartîncărcat deFDA Lawyers Blog
- Document2011-76-chartîncărcat deFDA Lawyers Blog
- DocumentACIBiosimilars2011încărcat deFDA Lawyers Blog
- DocumentCitizen Petitionîncărcat deFDA Lawyers Blog
- DocumentMedication Guides--Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)încărcat deFDA Lawyers Blog
- DocumentFDA Response to Generic Boniva Citizen Petitionîncărcat deFDA Lawyers Blog
- DocumentFDLI Policy Forum Vol 1, Issue 4încărcat deFDA Lawyers Blog
- DocumentPIVDisputes2011încărcat deFDA Lawyers Blog
- DocumentDisentangling Biobetters under the Biologics Price Competition and Innovation Act of 2009încărcat deFDA Lawyers Blog
- DocumentGraphic Health Warningsîncărcat deFDA Lawyers Blog
- DocumentSubstantial Equivalence Guidanceîncărcat deFDA Lawyers Blog
- DocumentACI Patent Term Adjustment and Patent Term Extension Conference 2011încărcat deFDA Lawyers Blog
- DocumentFDA Impact U.S. Medical Technology Innovationîncărcat deFDA Lawyers Blog
- DocumentACI PTA & PTE Conference Programîncărcat deFDA Lawyers Blog
- DocumentANDA Impurity Guidance 2010încărcat deFDA Lawyers Blog
- DocumentANDA Impurities Guidanceîncărcat deFDA Lawyers Blog
- Document39209531 Viropharma Complaintîncărcat deFDA Lawyers Blog
- DocumentCDRH 510(k) FDLI Presentation 3-26-08 -Re Program (00538574) (2)încărcat deFDA Lawyers Blog
- DocumentS. 3677încărcat deFDA Lawyers Blog
- DocumentEdit Deleteîncărcat deFDA Lawyers Blog